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Tuberous sclerosis complex is a genetic disorder
characterized by hamartomatous lesions in multiple
organs, frequently involving the kidney. We conducted
a retrospective review of the clinical and radiographic
records of 167 patients with tuberous sclerosis to determine
the frequency of renal disease, the likelihood of significant
renal morbidity, and the effects of genotype (TSC1 vs TSC2)
and gender on renal phenotype. Renal lesions were seen in
57.5% of patients. Of these, angiomyolipoma (AML) occurred
in 85.4%, cysts in 44.8%, and renal cell carcinoma in 4.2%.
Both AML and cysts were significantly more common and
more numerous in TSC2 than in TSC1. AML was significantly
more common in female than in male patients, but cysts
showed no correlation with gender. Eleven patients
developed renal abnormalities during their care in this
practice at an average age of onset of 11.3 years (range
3.8–23 years). The frequency and number of renal lesions
were positively correlated with age. Interventions, including
arterial embolization and nephrectomy, were performed
in 11 (6.6%) patients. Among female patients with
lymphangioleiomyomatosis, renal AML was universally
present. Our findings confirm a high rate of renal
involvement; a low rate of serious complications; significant
associations between renal involvement, genotype, and
gender; and a significant association between renal and
pulmonary involvement in female patients.
Kidney International (2006) 70, 1777–1782. doi:10.1038/sj.ki.5001853;
published online 27 September 2006
KEYWORDS: tuberous sclerosis complex; angiomyolipoma; cysts; renal cell
carcinoma; lymphangioleiomyomatosis
Tuberous sclerosis complex (TSC) is a genetic disorder
characterized by the growth of dysgenic lesions in multiple
organs including the brain, skin, kidney, heart, lungs, and
retina. TSC arises from inactivating mutations of either TSC1
(chromosome locus 9q34.3) or TSC2 (16p13.3), which
encode hamartin and tuberin, respectively. These proteins
are believed to function as tumor suppressors by forming a
complex that regulates cellular proliferation.1 Loss of
heterozygosity at the TSC2 locus has been observed in the
renal and pulmonary tumors associated with TSC,2–5
suggesting that tumor development follows loss of the
functional allele. Whereas mutations in TSC1 and TSC2
impact the same organ systems, TSC2 mutations tend to
result in a more severe clinical profile, including more acute
renal involvement.6,7
Renal manifestations occur with a high frequency and a
wide range of severity in TSC.8–10 Estimated rates of
involvement range from 4811 to 80%,10 with at least two
large studies reporting an incidence between 60 and 75%.12,13
Although the prevalence of renal findings in TSC is well
known, questions regarding age of onset, tumor growth rate,
frequency of clinical significance, and the effects of gender
and genotype remain unanswered.
The two renal pathologies most commonly seen in TSC
are angiomyolipomas (AMLs) and cysts. AMLs are more
prevalent, with a frequency in TSC of 34–80%.10,12–14
Generally seen in the cortex, AMLs are composed of
adipocytes, abnormal vasculature, and smooth muscle cells,
the proportions of which may vary even across lesions in a
single patient.8 The potential complications of AML include
hemorrhage, the risk of which increases with the size and
vascularity of the lesion, and mass effects, which can cause
discomfort or pain and can compromise renal function
by compressing urine outflow and/or distorting normal
renal parenchyma. Complications are generally treated by
angiographic arterial embolization or surgical extirpation,
with nephron-sparing procedures preferred to radical
nephrectomy.8,15 Some researchers have suggested that
certain AML variants are capable of metastatic growth,2,16
but this proposal remains controversial.
Renal AML in TSC is also associated with the develop-
ment of pulmonary lymphangioleimyomatosis (LAM), a
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 5 May 2006; revised 28 June 2006; accepted 3 August 2006;
published online 27 September 2006
Correspondence: EA Thiele, The Herscot Center for Tuberous Sclerosis
Complex, 175 Cambridge Street, Suite 340, Boston, Massachusetts 02114,
USA. E-mail: ethiele@partners.org
Kidney International (2006) 70, 1777–1782 1777
progressive cystic disease of the lungs affecting women
almost exclusively. AML is observed in approximately 88% of
patients with TSC and LAM17 and AML usually predates the
onset of pulmonary disease. However, the causes underlying
the association are poorly understood.
Renal cysts are observed with a frequency of 14–32% in the
TSC population,12–14 and exhibit two modes of presentation.
In the more common presentation, cysts are single or
multiple small lesions that are uniform in histology and
rarely symptomatic.10 Less commonly, TSC co-exists with
polycystic kidney disease, which carries a poor prognosis for
renal survival. These cysts are numerous, large, and
frequently symptomatic. The TSC2 locus is adjacent to one
of the genes for polycystic kidney disease (PKD1), and
contiguous deletions can produce both phenotypes.18 The
relationship between non-polycystic kidney disease renal
cysts and TSC genotype has not been well studied.
Anecdotal evidence suggests that renal cell carcinoma
occurs more frequently and at a younger age in TSC than in
the general population,13,19 although this has not been
confirmed.
This study investigates the epidemiology and sequellae
of renal disease in a cohort of 170 patients with TSC,
and examines whether genotype and gender predict renal
phenotype.
RESULTS
Subjects ranged in age from 1 month to 59 years (mean 15.7
years, s.d. 14.4). There was no significant difference in mean
age between male and female patients.
Mutational analysis had been performed on 136/167
patients (81.4%): 36 had mutations in TSC1 (26.4%), 75
had mutations in TSC2 (55.1%), and 23 patients who met the
clinical criteria for TSC had no identified mutation (NIM) by
standard genotyping (16.9%). Two patients had somatic
mosaicism of the TSC2 gene mutation and were excluded
from further analysis. One patient had disease-causing
mutations in both TSC genes. Given the greater severity of
the TSC2 phenotype,6,7,20 this patient was included in the
TSC2 subset. Two of the NIM patients had TSC2 poly-
morphisms known to be benign. The greater prevalence of
TSC2 over TSC1 mutations was consistent with prior studies,
as was the proportion of patients with NIM.6,20 There was no
significant relationship between genotype and gender;
however, patients with TSC2 were younger on average than
patients with TSC1 (P¼ 0.022; Table 1).
On average, between two and three radiology reports were
available per patient. Of 167 patients total, ultrasound had
been performed in 148 (88.6%), magnetic resonance imaging
(MRI) in 29 (17.4%), and computed tomographic (CT) in 29
(17.4%). Forty-one patients had undergone more than one
type of imaging. Twelve patients lacked radiology reports, but
were able to report their imaging findings to us in sufficient
detail to include them in analyses.
Renal lesions of any type were found in 96/167 (57.5%)
patients. Of the 96 renal patients, 82 (85.4%) had AML,
43 (44.8%) had cysts (of whom 30 had co-existing AML),
four (4.2%) patients had renal cell carcinoma, and three
(3.1%) had ambiguous diagnoses (i.e. renal cell carcinoma vs
fat-poor AML) in addition to known AML. Of the 30 female
patients aged 16 years and older, cystic lesions on pulmonary
CT consistent with LAM were observed in 10 (33.3%).
Six patients had a history of hemorrhagic episodes,
detected on imaging or by hematuria – five associated with
AMLs and one with cysts. A total of 11 patients underwent
invasive procedures, either for hemorrhagic AML or
suspected renal cell carcinoma. Five patients underwent
selective arterial embolization (mean age 23.6 years, range
5.8–37 years). Nine patients, including three who also had
embolization, underwent a nephrectomy (mean age 24 years,
range 6–37 years). One female patient with TSC2 had
progressive renal cell carcinoma confirmed by biopsy at our
institution, and died at the age of 28 years. No patient
progressed to end-stage renal disease while in our care.
A multiple regression analysis revealed that genotype had
a significant effect on renal phenotype, when gender and age
were controlled (Table 1). AMLs were significantly more
frequent (Po0.001), more numerous (Po0.001), and more
likely to be bilateral (Po0.001) in TSC2 than TSC1.
Similarly, cysts were more frequent (P¼ 0.025), more
numerous (P¼ 0.005), and more likely to be bilateral
(P¼ 0.047) in TSC2 than TSC1. Patients with TSC2 were
also more likely to have both lesion types (P¼ 0.005).
Patients with NIM appeared to have more extensive AML
involvement than patients with TSC1, but there were no
differences in the incidence or severity of cysts. Overall,
patients with NIM had renal phenotypes that more closely
resembled those of TSC2 than of TSC1, but they exhibited
fewer AMLs and a lower rate of bilateral AML presentation
than TSC2 patients.
There were too few cases of renal cell carcinoma to test its
correlation with gender or genotype. Of the four patients
with confirmed renal cell carcinoma, one had TSC1, two had
TSC2, and one had not been genotyped. Of the 11 patients
who have undergone embolization or nephrectomy for a
renal mass, three had not been tested, one had a mutation in
TSC1, five had mutations in TSC2, and two had NIM. There
were too few cases of invasive intervention to determine
whether genotype influences the likelihood of needing these
procedures.
McNemar’s test was performed to test the comparative
incidence of AMLs and cysts with respect to genotype. There
was no significant difference in the frequencies of these two
lesions in the NIM or TSC1 genotypes. In TSC2, however,
AMLs were significantly more common that cysts
(Po0.001).
AMLs were significantly more common in female than in
male patients (P¼ 0.006), even when genotype and age were
controlled, but the development of cysts was independent of
gender (Table 2). Female patients were also more likely to
have bilateral AMLs (P¼ 0.032) and a higher number of
AMLs (P¼ 0.014), whereas cysts showed no analogous effect.
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Also, female patients were more likely than male patients to
have both AMLs and cysts (P¼ 0.020).
When gender and genotype were controlled, age was
positively correlated with the presence, number, and
bilaterality of both AMLs and cysts, and with the likelihood
of having both lesion types (Table 2). The youngest patient to
exhibit renal findings was a 1-year-old TSC2 male patient
with bilateral cysts. Twelve patients in whom initial imaging
results were normal developed abnormal renal findings
during their care in our practice, at an average age of 11.1
years and a range of 3.8–23 years. Three patients developed
abnormal findings after the age of 20 years. There was
insufficient data to identify a ‘plateau age’ after which renal
lesions do not appear, nor to calculate meaningful rates of
progression. The most rapid growth of AMLs in this cohort
occurred in an asymptomatic TSC2 female patient whose
o5-mm bilateral AMLs at 13 years of age grew within 18
months to three large bilateral masses whose maximal
dimensions were 6.2, 6.0, and 3.2 cm, respectively. The first
imaging modality was ultrasound; the second was MRI.
Of the 30 female patients aged 16 years and older, 10
(33.3%) had cystic lesions on pulmonary CT consistent with
LAM (Table 1). Of the 10 patients with LAM, six had TSC2,
one had TSC1, and two had NIM. LAM was significantly
more common in female patients with TSC2 than TSC1
(P¼ 0.038). All patients with LAM had co-existing renal
AML, and the association between AML and LAM was
significant (Fisher’s exact test, P¼ 0.022).
DISCUSSION
Consistent with prior studies, we observed renal involvement
in a majority (57.5%) of individuals with TSC. Whereas the
prevalence of renal lesions in TSC is well known, little is
known about the variables that predict renal phenotype. A
better understanding of these factors will improve manage-
ment of the disease and provide insight into the pathogenesis
Table 1 | Genetic effects on renal involvement
TSC1 patients TSC2 patients NIM patients P-values P-values P-values
(N=36) (N=75) (N=23) TSC1 vs TSC2 TSC1 vs NIM TSC2 vs NIM
Male 14 (38.9%) 43 (57.3%) 11 (47.8%) NS NS NS
Agea 18.8715.8 (1.8–59.1) 12.6711.7 (0.1–49.9) 14.8714.2 (1.8–49.7) 0.022 NS NS
AML involvement
Frequency 8 (22.2%) 45 (60%) 11 (47.8%) o0.001 0.006 NS
Number
1 5 (62.5%) 1 (2.2%) 2 (18.2%) o0.001 0.002 0.031
2–4 2 (25%) 1 (2.2%) 0 o0.001 0.001 —
44 1 (12.5%) 43 (95.6%) 9 (81.8%) — — 0.023
— — —
Bilateral lesions 2 (25%) 44 (97.8%) 9 (81.8%)
Cystic involvement
Frequency 6 (16.7%) 23 (30.7%) 6 (26.1%) 0.025 NS NS
Numberb
1 4 (66.7%) 7 (30.4%) 2 (33.3%) 0.005 NS NS
2–4 0 2 (8.7%) 0 0.047 NS NS
44 1 (16.7%) 13 (56.5%) 4 (66.7%)
Bilateral lesions 1 (16.7%) 12 (52.2%) 4 (66.7%)
AML and cystsc 2 (5.6%) 19 (25.3%) 3 (13.0%) 0.005 NS NS
RCC 1 (2.8%) 2 (2.7%) 0 NS NS NS
Complications/interventions
Hemorrhage 0 3 (4%) 1 (4.3%) NS NS NS
SAE 0 3 (4%) 1 (4.3%) NS NS NS
Nephrectomy 1 (2.8%) 3 (4%) 2 (8.7%) NS NS NS
LAMd 1/9 (11.1%) 6/10 (60.0%) 2/4 (50.0%) 0.038 NS NS
AML, angiomyolipoma; LAM, lymphangioleiomyomatosis; NIM, no identified mutation; NS, nonsignificant; RCC, renal cell carcinoma; SAE, selective arterial embolization;
TSC, tuberous sclerosis complex.
Gender vs genotype was assessed with the w2 test; age vs genotype was assessed with Student’s t-test; LAM vs genotype was assessed with Fisher’s exact test. All other
variables were tested for differences between genotypes with a multiple logistic regression, controlling for age and gender. Pairwise comparisons of TSC1, TSC2, and NIM
were performed.
aAge on most recent renal study. Mean7s.d. (range).
bThe number of cysts was unavailable for one TSC1 patient and one TSC2 patient with known cystic involvement.
cPatients with both lesions types were compared to patients with either lesion type or neither.
dIncluding only females of age X16 after Dabora et al.6 P-values were derived from Fisher’s exact test.
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of TSC-related tumors both of the kidney and of other
organs.
Effects of genotype
TSC genotype is a strong predictor of renal involvement.
Patients with TSC2 mutations exhibited a higher incidence
and severity of both AMLs and cysts, compared to patients
with TSC1 (Table 1). These results demonstrate the utility of
genetic testing in the clinical care of patients with TSC, as
renal outcomes can be more accurately predicted if muta-
tional results are known. Although severe renal disease
including renal cell carcinoma can occur in TSC1, patients
with TSC1 mutations are overall significantly less likely to
exhibit renal manifestations than those with TSC2. A larger
sample is needed to determine whether there is an effect of
genotype on the development of renal cell carcinoma and the
likelihood of needing invasive intervention.
TSC patients who have NIM generally exhibit an overall
syndromic phenotype that is less severe than patients with
known mutations, especially with respect to cognitive and
seizure outcomes.6,7 However, this phenomenon is not
recapitulated in the renal phenotype. Sancak et al.7 observed
that AMLs were more common in patients with NIM than in
those with TSC1. Dabora et al.6 observed a higher grade of
AML involvement in patients with NIM than in TSC1 and no
difference between NIM and TSC2. Similarly, our findings
suggest that the renal phenotype of patients with NIM more
closely resembles that of TSC2 than TSC1. This suggests that
NIM patients may have a transcriptional, translational, or
post-translational defect in TSC2, and that these patients
warrant closer examination of their TSC2 sequence and
protein activity.
It is worth noting that patients with TSC2 mutations were
younger on average than patients with TSC1 mutations.
Given that TSC2 mutations often result in a more severe
clinical profile, it is likely that patients with TSC2 come to
medical attention at a younger age.
Effects of gender
The relationship between gender and renal phenotype was
significant only for AML involvement (Table 2). AMLs were
more common and more numerous in female patients, after
controlling for age and genotype. Sporadic AML is known to
exhibit predominance in female patients,8,15 an effect that has
been attributed to the presence of estrogen and progesterone
receptors on the tumors.8 Other studies of TSC have
suggested that AMLs may show a greater propensity for
growth in female patients.10,14 Further study is needed to
determine whether hormonal modulation accounts for the
difference in AML manifestations between female and male
patients.
Age of onset and rate of growth
Our data show a significant association between increasing
age and the incidence and number of both AMLs and cysts.
This association was independent of the effects of gender and
genotype and confirms prior observations that both lesion
types increase in frequency with age.21 These results highlight
the importance of following patients with TSC for renal
involvement throughout their adult lives.
Other studies have estimated the average age at onset of
renal abnormalities to be between 7.2 and 9.2 years for AMLs
10,21 and 9 years for cysts.21 Our results suggest a later onset
(average 11.1 years). However, retrospective studies may
overestimate age of onset, as patients with normal findings
are not followed as frequently as those with abnormal ones.
Prior studies have suggested that cysts may be present at
birth, whereas AMLs begin appearing in the first year of life.10
It is often assumed that patients with renal involvement will
develop lesions by adolescence; however, it is unknown
whether there is a plateau age after which renal lesions are
unlikely to develop. Little is known about the growth rate of
AMLs in TSC or the likelihood that they will remain stable
over time.
Although our results support the notion that renal
involvement usually develops by adolescence, two cases from
this population offer instructive and important examples to
the contrary. In one case, a female patient who had had a
normal renal ultrasound at age 21 years was found on routine
ultrasound at age 23 years to have a 3.6 3.1 3.9cm solid
mass suspicious for renal cell carcinoma. In another case,
multiple small AMLs were detected on routine ultrasound
in a 20-year-old male patient who had had a normal
ultrasound at age 18 years. The sensitivity and subjectivity of
ultrasound is such that lesions are sometimes missed on a
single study. However, these examples demonstrate the
critical importance of obtaining follow-up renal imaging
for patients with TSC throughout adulthood, even if scans
Table 2 | Effects of gender and age on renal involvement
Male Female P-values P-values
(N=68) (N=66) M vs F Age
AML involvement
Frequency 25 (36.8%) 39 (59.1%) 0.006 o0.001
Number
1 1 (4.0%) 7 (17.9%) 0.014 o0.001
2–4 1 (4.0%) 2 (5.1%)
44 23 (92.0%) 30 (76.9%)
Bilateral lesions 23 (92.0%) 32 (82.1%) 0.032 o0.001
Cystic involvement
Frequency 15 (22.0%) 20 (30.3%) NS 0.040
Number
1 4 (26.7%) 9 (45.0%) NS 0.005
2–4 2 (13.3%) 0
44 8 (53.3%) 10 (50.0%)
Bilateral lesions 8 (53.3%) 9 (45.0%) NS 0.037
AML and cysts 7 (10.3%) 17 (25.8%) 0.020 0.027
AML, angiomyolipoma; F, female; M, male.
Type III P-values were determined from a multiple logistic regression with terms for
genotype, age, and gender. Includes only patients who had undergone genetic
testing. Both AMLs and cysts increased in frequency, number, and bilaterality with
age. P-values show the effect of an increase in age on the likelihood of having the
symptom described. The number of cysts was unavailable for one male and one
female patient with known cystic involvement.
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are normal through adolescence. We cannot rule out the
possibility that renal lesions may develop in adulthood
without a better understanding of the molecular mechanisms
by which they form.
Given the retrospective nature of the study, we were
unable to estimate tumor growth rate. Measurements of
lesions size were hindered by the use of different imaging
modalities on consecutive scans and by the lack of size
estimates in many radiology reports. Comparisons across
different modalities are complicated by differences in power
and resolution, and the user-dependent nature of ultrasound
compared to the more objective nature of CT and MRI. To
our knowledge, there are no large-scale studies indicating
that one modality provides measurably better detection than
others in TSC.
More studies are needed to determine optimal surveillance
protocols for renal imaging in TSC. We currently recommend
that pediatric TSC patients have a baseline renal ultrasound
before 5 years of age. If results are normal, follow-up
ultrasound should be obtained every 2–3 years. If results
show AMLs or cysts, we recommend follow-up ultrasound
yearly thereafter. If results are suspicious for renal cell
carcinoma, we recommend MRI for re-evaluation and
follow-up imaging at six-month intervals or more frequently
if clinically indicated. The case of rapid growth in multiple
AMLs in a patient under 15 years of age underscores the
importance of yearly imaging in patients with known renal
involvement.
Differentiating AML from renal cell carcinoma
Renal cell carcinoma has been observed in the TSC
population in children as young as 2 years of age,22 but
debate continues over whether TSC mutations increase
susceptibility to renal cell carcinoma8,23 and whether TSC-
related AML can progress to carcinoma.9 Some authors have
suggested that certain variants of AML are capable of
metastatic growth resembling carcinoma;2,16 however, this
issue remains highly contested.
A persistent problem in diagnosing renal masses in TSC is
the difficulty in distinguishing fat-poor AML from renal cell
carcinoma on imaging. In this cohort, there were four
pathologically confirmed cases of renal cell carcinoma. There
were six additional cases of renal masses that could not be
differentiated between AML and carcinoma on imaging,
constituting a significant management dilemma. Biopsy is
often discouraged, as it can cause highly vascular AMLs to
hemorrhage and can scatter malignant carcinoma cells.
Moreover, ambiguous lesions often exhibit ambiguous
pathology. Nephrectomy must be undertaken with caution
in TSC, as patients are predisposed to developing additional
masses in the remaining kidney.
This issue is of significant concern in the treatment of
renal masses in TSC. A clearer understanding of the natural
history of AML is urgently needed. It will also be essential to
determine the accuracy of radiographic diagnoses in order to
reduce the reliance on surgical intervention.
Symptomatic complications
Our results suggest that renal lesions in TSC are infrequently
symptomatic and rarely fatal. Nine (9.4%) of 96 patients with
known renal lesions had undergone biopsy or nephrectomy
for AML or renal cell carcinoma. Six (6.3%) had hemorrhagic
episodes. One patient died of renal cell carcinoma. None had
end-stage renal disease while being followed in this practice.
Therefore, we emphasize that, although close follow-up is
critical for all patients with renal involvement, the rate
of significant renal morbidity in the overall TSC population
is low.
Coincidence of AML and LAM
The association between AML and LAM in TSC is well
known.8,17,24–26 LAM is characterized by the proliferation of
abnormal smooth muscle cells in the interstitial spaces of the
lung, and affects female subjects almost exclusively.8,27,25
Renal AML is seen in approximately 88% of TSC-related
LAM and 30% of sporadic LAM.28 Despite their co-
occurrence, the relationship between these two pathologies
is not well understood. One hypothesis suggests that both
diseases result from aberrant function of the TSC2 gene
product in separate organs.24,26 Loss of heterozygosity in
TSC2 has been observed in both sporadic and TSC-related
LAM 5,28 and re-expression of the TSC2 gene product appears
to block the invasive migration of LAM cells in vitro.26 These
observations are also consistent with a second hypothesis
suggesting that LAM arises through the non-malignant
metastasis of AML cells from the kidney. This view is
supported by evidence that LAM can recur following
pulmonary transplant, exhibiting cells that are both patient-
and donor-derived, and that women with larger AMLs are
more likely to have LAM.27,25 Furthermore, identical loss of
heterozygosity loci have been observed in AML and LAM
cells in patients with sporadic disease, suggesting a common
cellular origin.27
In this cohort, all 10 of the female patients who exhibited
pulmonary LAM also exhibited renal AML. This significant
correlation (P¼ 0.022) suggests that AML is co-requisite with
LAM and supports the hypothesis of non-malignant
metastasis. Whereas LAM can occur in any TSC genotype,
it is most common in TSC2, possibly owing to the
predominance of AML in TSC2. Given that LAM was
observed in 10/30 (33%) female patients over the age of
16 years, we recommend that all female patients with TSC be
followed throughout adulthood for pulmonary involvement.
Conclusion
Renal involvement is common in TSC, but symptomatic
complications are rare. Genotype, gender, and increasing age
were shown to have significant effects on renal manifesta-
tions. The severity of renal involvement is markedly increased
in TSC2 compared to TSC1, female subjects have more
extensive AML involvement than male subjects, and both the
frequency and number of AMLs and cysts are positively
correlated with age. Among patients with LAM, AML was
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universally coincident, providing further evidence for a
relationship between these pathologies. More studies are
needed to determine the rate of growth and age of onset of
renal lesions in TSC. Importantly, our findings indicate that
renal lesions can develop after puberty, emphasizing the need
to monitor patients with TSC for potential renal involvement
throughout their adult lives.
MATERIALS AND METHODS
We conducted a retrospective review of the clinical and radiographic
records of 203 patients who were followed for TSC by a single
neurologist (EAT). Clinical consult notes were reviewed to ensure
that all subjects met established diagnostic criteria for TSC.29 Renal
radiology reports were available for 170 patients; those without
imaging records were excluded from the study. Three patients had a
single renal mass that could not be differentiated between AML and
renal cell carcinoma; these three were excluded from all analyses for
a total sample size of 167 (79 female patients).
A total of 433 CT, MRI, and ultrasound reports were reviewed for
descriptions of renal findings. When sequential scans were available,
results were compared for evidence of lesion growth. Subjects’
reported ages correspond to the date of their most recent renal scan.
Radiology reports from chest CT scans on all female subjects over
the age of 16 years (after Dabora et al.6) were reviewed for the
presence of LAM. Mutational analyses with respect to TSC1 and
TSC2 were completed at Athena Diagnostics (Worcester, MA, USA)
and Massachusetts General Hospital (Boston, MA, USA).
The w2 test was used to assess the relationship between gender and
genotype. Student’s t-test was used to test age vs genotype. Fisher’s
exact test was used to test LAM vs genotype and AML vs LAM. The
effect of genotype on the frequency, number, and bilaterality of
AMLs and cysts was tested using a multiple regression (logistic for
categorical variables, linear for continuous) controlling for age and
gender. Pairwise comparisons of TSC1, TSC2, and NIM were per-
formed. The effects of gender and increasing age on renal mani-
festations were assessed using a multiple regression, controlling for
genotype. In all cases, statistical significance was defined as Po0.05.
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